

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Alta Vista Ventures Ltd.
Suite 459 – 409 Granville Street
Vancouver, BC V6C 1T2

Item 2 Date of Material Change

November 10, 2015

Item 3 News Release

The news release was disseminated on November 10, 2015.

Item 4 Summary of Material Change

Alta Vista Ventures Ltd. (AVV-CSE) is pleased to announce that it has signed a formal agreement to purchase Thor Pharma Ltd. Thor Pharma is based in Burlington Ontario and has an MMPR (Marijuana for Medical Purposes Regulations) application with Health Canada.

Item 5 Full Description of Material Change

See attached news release.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable

Item 7 Omitted Information

None

Item 8 Executive Officer

For more information, please contact Ian Foreman, President & CEO, Telephone:
604.678.2531

DATED: November 10, 2015

“Ian Foreman”

Per: Ian Foreman
 President and Chief Executive Officer

ALTA VISTA VENTURES LTD.

AVV – CSE
News Release #15-10

November 10, 2015

Alta Vista signs Formal Agreement to purchase Thor Pharma

Alta Vista Ventures Ltd. (AVV-CSE) is pleased to announce that it has signed a formal agreement to purchase Thor Pharma Ltd. Thor Pharma is based in Burlington Ontario and has an MMPR (Marijuana for Medical Purposes Regulations) application with Health Canada.

Thor Pharma's application is for the production and sale of up to 10,000,000 grams of dried marijuana per year. Thor Pharma has a lease agreement for a 75,000 square foot commercial building and has plans to utilize up to 55,000 square feet of space for the cultivation of marijuana upon the issuance of a license by Health Canada. The lease for the building stipulates that no rent will be paid until Thor Pharma receives the 'ready to build' letter from Health Canada.

Alta Vista is committed to expanding in the resurgent medical marijuana industry as the Company has looked at a number of additional opportunities.

Alta Vista has the right to purchase Thor Pharma via an Assignment and Novation Agreement from Shaxon Enterprises by paying \$1,000,000 and issuing 10,000,000 shares on a graduated basis as the Thor Pharma application moves through the licensing process with Health Canada. Alta Vista now has 30 days to make a \$100,000 payment and issue 5,000,000 shares. Shaxon Enterprises will have a 10% royalty on net profits of Thor Pharma. The Assignment and Novation Agreement allows for Alta Vista to assume the purchase of Thor Pharma for \$1,500,000 from the underlying owners in staged payments that terminate on the third year anniversary of the issuance of a license from Health Canada.

Alta Vista cannot guarantee nor estimate the timing for the issuance of an MMPR license to Thor Pharma.

On behalf of the Board,

"Ian Foreman"

Ian Foreman

President

For information on Thor Pharma please contact Mr. Don Shaxon at 289-697-8625.
For additional information on Alta Vista Ventures please call the Company at 604-678-2531.

Neither Canadian Securities Exchange (CSE) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties. As a result, actual results may vary materially from those described in the forward-looking statements.